Supplementary Table S1: Characteristics of NPC patients and healthy controls included in the study.

Characteristics		Bax -248 G>A Case/Control: 70/70		Bcl2 -938 C>A Case/Control: 92/68	
		Case (%)[†]	Control (%)	Case (%)	Control (%)
Gender	Male	48 (68.6)	51 (72.9)	62 (67.4)	44 (64.7)
	Female	22 (31.4)	19 (27.1)	30 (32.6)	24 (35.29)
Age (Year)	<28	6 (8.6)	5 (7.1)	12 (13.4)	4 (5.9)
	28-50	41 (58.6)	41 (58.6)	57 (61.9)	24 (35.3)
	>50	23 (32.9)	24 (34.3)	23 (25.0)	25 (36.8)
Addiction	Tobacco	22 (31.4)	4 (5.7)	31 (33.7)	4 (5.9)
	Areca Nut	16 (22.9)	0	13 (14.1)	0
	Betel Nut	15 (21.4)	2 (2.9)	27 (29.3)	1 (1.5)
	Alcohol	17 (24.3)	5 (7.1)	19 (20.7)	5 (7.4)
Specific Clinical symptoms	Ear Ache	24 (34.3)	1 (1.4)	38 (41.3)	1 (1.5)
	Deafness	18 (25.7)	2 (2.9)	32 (34.8)	3 (4.4)
	Infection	9 (12.9)	0	10 (10.9)	0
	Tinnitus	11 (15.7)	1 (1.4)	11 (11.9)	1 (1.5)
	Obstruction	19 (27.1)	2 (2.9)	27 (29.3)	2 (3.0)
	Bleeding	22 (31.4)	2 (2.9)	22 (23.9)	2 (3.0)
	Congestion	18 (25.7)	3 (4.3)	29 (31.5)	3 (4.4)
	Headache	26 (37.1)	4 (5.7)	39 (42.4)	3 (4.4)
Clinical Examination[‡]	Cranial nerve palsy	17 (24.3)	1 (1.4)	24 (26.1)	1 (1.5)
	Lymphoadenopathy	33 (47.1)	2 (2.9)	46 (50.0)	3 (4.4)
	Keratinizing squamous cell carcinoma	38 (54.3)	NE	47 (51.1)	NE
	Nonkeratinizing differentiated carcinoma	14 (20.0)	NE	25 (27.2)	NE
	Undifferentiated carcinoma	18 (25.7)	NE	20 (21.7)	NE
TNM staging[§]	stage 0: T_{is}, N_0, M_0	0	NE	1 (1.1)	NE
	stage I: T_1, N_0, M_0	3 (4.3)	NE	6 (6.5)	NE
	stage II: T_2, N_0, M_0 (or T_1 /T_2, N_1, M0)	28 (40.0)	NE	33 (35.9)	NE
	stage III: T_3, N_0 to N_2, M_0 (or T_1 /T_2, N_2, M_0)	15 (21.4)	NE	19 (20.7)	NE
	stage IVA: T_4, N_0, N_1/ N_2, M_0	22 (31.4)	NE	26 (28.3)	NE
	stage IVB: any T, N_3, M_0	2 (2.9)	NE	5 (5.4)	NE
	stage IVC: any T, any N, M_1	0	NE	2 (2.2)	NE

T: tumor; N: lymph node; M: metastasis; NE, Not Examined. The subjects are marked and the Data are the number of participants unless otherwise specified.

[†] Frequency distribution is denoted by %.

[‡] According to the WHO histopathological grading system and

[§] According to AJCC classification system.

Supplementary Table S2: Survival analysis by Kaplan-Meier log-rank test.

BAX -248 G>A	Estimate Survival Mean ± SE	Estimated Proportion Surviving at 5 years	Chi-squared	DF	P-value
GG	47.346 ±1.043	54.00	26.6436	2	< 0.0001
GA	35.900 ±1.035	52.63			
AA	32.000 ±0.000	0.00			
GA+AA	35.692 ±1.001	50.00	18.1428	1	< 0.0001
GG	47.346 ±1.043	54.00			
BCL2 -938 C>A					
CC	55.111 ±1.135	82.35	23.2897	2	<0.0001
CA	46.926 ±2.460	60.71			
AA	38.423 ±1.808	30.77			
CA+AA	45.114 ±1.969	51.22	17.0379	1	< 0.0001
CC	55.218 ±1.109	82.35			
GA+CA dual positive	41.657 ±1.563	28.57	14.5348	1	0.0001
Others	51.799 ± 1.035	87.30			

Abbreviation: SE: standard error, DF: Degrees of freedom.

†P value <0.05 was considered significant

Supplementary Table S3: Computational analysis for the Transcription factors binding affinity changes.

SNP	TFs	Weight Score $_{SNP}$ (p)	Weight Score $_{Ref}$ (p)	Absolute log(p) difference	Predicted binging region
Bax (-248) G>A	HIF1	1.856 (0.547)	5.748 (0.066)	-0.914	TGGACGGGCGGC
	SP1	0.764 (0.726)	2.726 (0.687)	-0.024	TTGGACGGGC
BCL2 (-938) C>A	PAX3	6.308 (0.006)	2.502 (0.089)	1.143	TCGTCCCCTCTCC
	CREB	3.697(0.082)	0.652 (0.465)	0.750	TCGTCCCATCTCCCC
	PAX9	2.927 (0.338)	5.760 (0.063)	-0.724	ATCGTCCCATCTCCCC TGTCTCTCTCCT

Abbreviation: SNP: Single Nucleotide Polymorphism, TFs: Transcription Factors.

Supplementary Table S4: Meta-analysis results of the BAX -248 G>A association with tissue-specific cancer in the overall and stratified study.

Study comparison	Forest plot analysis			Heterogeneity			
	OR	95% CI	P -value	Q-value[†]	P_Q[‡]	I^2 (%)[§]	Model
Overall studies							
A vs G	1.23	0.98, 1.55	0.06	54.24	<0.05	74.19	Random
AA vs GG	1.79	1.31, 2.43	0.00	20.24	>0.05	40.73	Fixed
GA vs GG	1.13	0.92, 1.38	0.22	29.55	<0.05	52.63	Random
AA+GA vs GG	1.21	0.97, 1.52	0.09	40.99	<0.05	65.84	Random
AA vs GG+GA	1.73	1.28, 2.33	0.00	18.93	>0.05	36.62	Fixed
Carcinomas							
A vs G	1.60	1.09, 2.34	0.01	19.41	<0.05	74.24	Random
AA vs GG	2.61	1.68, 4.06	0.00	3.57	>0.05	0.00	Fixed
GA vs GG	1.31	0.93, 1.86	0.12	10.42	>0.05	52.03	Random
AA+GA vs GG	1.53	1.04, 2.25	0.02	14.10	<0.05	64.54	Random
AA vs GG+GA	2.53	1.65, 3.87	0.00	3.21	>0.05	0.00	Fixed
Other Malignancies							
A vs G	1.05	0.78, 1.41	0.73	29.89	<0.05	73.24	Random
AA vs GG	1.25	0.81, 1.91	0.30	11.07	>0.05	36.78	Fixed
GA vs GG	1.05	0.79, 1.38	0.72	18.76	<0.05	57.37	Random
AA+GA vs GG	1.06	0.78, 1.44	0.69	24.91	<0.05	67.88	Random
AA vs GG+GA	1.21	0.80, 1.83	0.36	9.79	>0.05	28.55	Fixed

Abbreviation: OR: Odd Ratio, 95% CI: Confidence Intervals, Q: Cochran's Q test, P_Q: P-value of the Cochran's Q test, Random: Random-effect model, Fixed: Fixed-effect model.

[†] Q is distributed as a chi-square statistic with number of studies minus 1 degree of freedom

[‡] P with <0.05 was considered significant

[§] I^2 statistic describes the percentage of variation across studies that is due to heterogeneity rather than chance

Supplementary Table S5: Distribution of Bax (-248) G>A genotypes of NPC cases and controls of different cancers included in the meta-analysis.

Study	Control/ Case	Genotype (Control)			Genotype (Case)			MAF (control/ Case)	HWE	
		GG	GA	AA	GG	GA	AA		χ2	P value†
Chen K et al, 2007	934/814	723	200	11	627	170	17	0.11/0.12	0.46	0.49
Cingeetham A et al, 2015	305/218	253	48	4	193	25	0	0.09/0.05	0.96	0.32
Dholariya et al 2016	70/70	47	19	4	34	24	12	0.19/0.34	1.14	0.28
Edathara PM et al, 2016	509/477	429	74	6	42	54	2	0.08/0.06	1.84	0.17
Javid J et al, 2015	160/160	90	51	19	70	43	47	0.27/0.42	6.80	0.009
Mirmajidi H. et al, 2015	89/100	67	21	1	69	31	0	0.12/0.15	0.20	0.64
Mozhagan Moazami, 2016	62/62	24	25	13	23	24	15	0.41/0.43	1.73	0.18
Nuckel H et. Al, 2006	95/112	79	15	1	87	21	4	0.08/0.12	0.09	0.76
Oliveira C et al, 2014	215/200	167	43	5	163	35	2	0.12/0.09	1.42	0.23
Present study, 2018	70/70	66	4	0	52	17	1	0.02/0.13	0.06	0.80
Saxena A et al, 2002	25/34	24	1	0	22	12	0	0.02/0.17	0.01	0.91
Skogsberg A et al, 2006	207/463	163	40	4	373	84	6	0.11/0.10	0.68	0.40
Starczynski J et al, 2005	135/203	115	19	1	157	44	2	0.07/0.11	0.04	0.84
Wang WL et al, 2014	446/424	340	90	16	287	108	29	0.13/0.19	9.43	0.002
Yildiz Y et al, 2013	82/53	63	19	0	40	13	0	0.11/0.12	1.40	0.23

Abbreviation: MAF: minor allele frequency; HWE: Hardy–Weinberg equilibrium

†P-value >0.05 was considered significant

Supplementary Table S6: Meta-analysis results of the BCL2 -398 C>A association with tissue-specific cancer in the overall and stratified study.

Study comparison	Forest plot analysis			Heterogeneity			
	OR	95% CI	P -value	Q-value[†]	P_Q[‡]	I^2 (%)[§]	Model
Overall studies							
A vs C	0.98	0.81, 1.17	0.83	133.22	<0.05	88.74	Random
AA vs CC	0.93	0.64, 1.37	0.74	127.83	<0.05	88.26	Random
CA vs CC	0.96	0.79, 1.17	0.74	61.63	<0.05	75.66	Random
AA+CA vs CC	0.95	0.76, 1.19	0.70	95.08	<0.05	84.22	Random
AA vs CC+CA	0.97	0.71, 1.33	0.88	103.80	<0.05	85.55	Random
Carcinomas							
A vs C	0.88	0.74, 1.06	0.18	81.36	<0.05	85.25	Random
AA vs CC	0.75	0.51, 1.09	0.14	76.07	<0.05	84.22	Random
CA vs CC	0.87	0.71, 1.07	0.29	40.66	<0.05	70.49	Random
AA+CA vs CC	0.85	0.68, 1.07	0.18	61.61	<0.05	80.52	Random
AA vs CC+CA	0.81	0.60, 1.10	0.19	62.40	<0.05	80.77	Random
Other Malignancies							
A vs C	1.45	1.26, 1.66	0.00	0.52	>0.05	0.00	Fixed
AA vs CC	2.07	1.15, 3.72	0.01	7.39	<0.05	72.94	Random
CA vs CC	1.33	0.97, 1.82	0.07	4.30	>0.05	53.84	Random
AA+CA vs CC	1.42	1.18, 1.72	0.00	0.60	>0.05	0.00	Fixed
AA vs CC+CA	1.89	1.02, 3.50	0.04	8.87	<0.05	77.46	Random

Abbreviation: OR: Odd Ratio, 95% CI: Confidence Intervals, Q: Cochran's Q test, P_Q: P-value of the Cochran's Q test, Random: Random-effect model, Fixed: Fixed-effect model.

[†] Q is distributed as a chi-square statistic with number of studies minus 1 degree of freedom

[‡] P with <0.05 was considered significant

[§] I^2 statistic describes the percentage of variation across studies that is due to heterogeneity rather than chance

Supplementary Table S7: Distribution of BCL2 -938 C>A genotypes in cases and controls of different cancers included in the meta-analysis.

Study	Control/ Case	Genotype (Control)			Genotype (Case)			MAF (control/ Case)	HWE	
		CC	CA	AA	CC	CA	AA		$\chi 2$	P value[†]
Bachmann HS et al, 2007	120/274	21	63	36	58	140	76	0.56/0.53	0.53	0.46
Christian DF et al, 2010	40/40	12	18	10	14	21	5	0.47/0.38	0.38	0.53
Cingeetham A et al, 2015	305/221	229	37	39	144	47	30	0.18/0.24	111.08	0.00
Hirata H et al, 2008	209/216	101	72	36	92	83	41	0.34/0.38	11.34	0.0006
Javid J et al, 2014	155/155	31	68	56	56	71	28	0.58/0.40	1.52	0.21
Lehnerdt GF et al, 2009	150/133	26	80	44	38	59	36	0.56/0.49	1.01	0.31
Li W et al, 2014	252/248	128	105	19	109	103	36	0.28/0.35	0.15	0.69
Meka PB et al, 2015	204/110	116	81	7	58	38	14	0.23/0.30	2.53	0.11
Moghaddam E et al,2017	130/120	29	65	36	34	74	12	0.52/0.40	0.001	0.97
Mou X et al, 2015	129/200	52	50	27	90	95	15	0.40/0.31	3.20	0.07
Pan W et al, 2015	1600/1587	510	828	262	658	718	211	0.42/0.35	5.82	0.01
Present study, 2018	68/92	54	11	3	51	28	13	0.12/0.29	4.61	0.03
Wang WL et al, 2014	446/424	191	223	32	147	198	79	0.32/0.41	1.59	0.20
Xu P et al, 2013	1017/1017	393	479	145	378	483	156	0.37/0.39	0.002	0.96
Yang X et al, 2016	1040/520	306	544	190	228	238	54	0.44/0.33	3.66	0.05
Zhang N et al, 2011	107/114	46	53	8	42	53	19	0.32/0.39	1.91	0.16

Abbreviation: MAF: minor allele frequency; HWE: Hardy–Weinberg equilibrium

[†] P-value >0.05 was considered significant

Supplementary Figure S1: Identification and selection of the study for Meta-analysis.



Supplementary Figure S1

Supplementary Figure S2: Sensitivity analysis of BAX -248 G>A polymorphism with overall cancer. The odds ratios (OR) are represented by the square, the 95% CIs are denoted by horizontal lines and the diamond signifies the pooled OR for each allelic and genetic combination



A vs G

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
Chen K et al, 2007	1.270	0.975	1.656	1.770	0.077
Cingeetham A et al , 2015	1.299	1.035	1.631	2.259	0.024
Dholariya et al 2016	1.185	0.941	1.493	1.440	0.150
Edathara PM et al, 2016	1.297	1.032	1.631	2.226	0.026
Javid J et al, 2015	1.178	0.937	1.481	1.403	0.161
Mirmajidi H et al , 2015	1.239	0.974	1.578	1.742	0.081
Mozhagan Moazami, 2016	1.251	0.980	1.595	1.800	0.072
Nuckel H et al, 2006	1.223	0.963	1.553	1.649	0.099
Oliveira C et al, 2014	1.285	1.013	1.629	2.070	0.038
Present study, 2017	1.177	0.946	1.466	1.460	0.144
Saxena A et al, 2002	1.205	0.964	1.506	1.639	0.101
Skogsberg A et al, 2006	1.277	1.001	1.630	1.968	0.049
Starczynski J et al, 2005	1.216	0.957	1.546	1.599	0.110
Wang WL et al, 2014	1.214	0.948	1.556	1.536	0.125
Yildiz Y et al, 2013	1.248	0.983	1.584	1.822	0.068
Combined	1.236	0.984	1.553	1.819	0.069

AA vs GG

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
Chen K et al, 2007	1.792	1.284	2.501	3.431	0.001
Cingeetham A et al , 2015	1.841	1.354	2.503	3.892	0.000
Dholariya et al 2016	1.692	1.234	2.320	3.263	0.001
Edathara PM et al, 2016	1.906	1.396	2.602	4.061	0.000
Javid J et al, 2015	1.486	1.046	2.112	2.209	0.027
Mirmajidi H et al , 2015	1.818	1.338	2.472	3.818	0.000
Mozhagan Moazami, 2016	1.877	1.359	2.593	3.818	0.000
Nuckel H et al, 2006	1.766	1.297	2.404	3.613	0.000
Oliveira C et al, 2014	1.886	1.382	2.574	4.000	0.000
Present study, 2017	1.778	1.308	2.417	3.675	0.000
Skogsberg A et al, 2006	1.903	1.389	2.606	4.007	0.000
Starczynski J et al, 2005	1.796	1.320	2.444	3.727	0.000
Wang WL et al, 2014	1.693	1.194	2.401	2.954	0.003
Combined	1.790	1.319	2.430	3.736	0.000

GA vs GG

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
Chen K et al, 2007	1.173	0.927	1.484	1.330	0.183
Cingeetham A et al , 2015	1.179	0.959	1.449	1.561	0.119
Dholariya et al 2016	1.109	0.902	1.363	0.979	0.327
Edathara PM et al, 2016	1.184	0.961	1.459	1.590	0.112
Javid J et al, 2015	1.145	0.921	1.425	1.217	0.224
Mirmajidi H et al , 2015	1.120	0.907	1.385	1.052	0.293
Mozhagan Moazami, 2016	1.145	0.926	1.416	1.254	0.210
Nuckel H et al, 2006	1.131	0.915	1.399	1.138	0.255
Oliveira C et al, 2014	1.168	0.942	1.449	1.417	0.156
Present study, 2017	1.076	0.900	1.286	0.804	0.422
Saxena A et al, 2002	1.101	0.913	1.327	1.008	0.313
Skogsberg A et al, 2006	1.165	0.935	1.452	1.362	0.173
Starczynski J et al, 2005	1.101	0.895	1.354	0.911	0.363
Wang WL et al, 2014	1.104	0.891	1.368	0.903	0.366
Yildiz Y et al, 2013	1.141	0.923	1.411	1.221	0.222
Combined	1.134	0.927	1.388	1.221	0.222

AA+GA vs GG

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
Chen K et al, 2007	1.261	0.968	1.642	1.718	0.086
Cingeetham A et al , 2015	1.277	1.016	1.605	2.094	0.036
Dholariya et al 2016	1.173	0.932	1.475	1.360	0.174
Edathara PM et al, 2016	1.279	1.015	1.611	2.087	0.037
Javid J et al, 2015	1.185	0.934	1.504	1.399	0.162
Mirmajidi H et al , 2015	1.212	0.954	1.541	1.572	0.116
Mozhagan Moazami, 2016	1.231	0.969	1.563	1.701	0.089
Nuckel H et al, 2006	1.210	0.953	1.535	1.565	0.118
Oliveira C et al, 2014	1.265	0.996	1.606	1.925	0.054
Present study, 2017	1.153	0.933	1.424	1.316	0.188
Saxena A et al, 2002	1.181	0.951	1.467	1.503	0.133
Skogsberg A et al, 2006	1.259	0.985	1.609	1.843	0.065
Starczynski J et al, 2005	1.190	0.939	1.508	1.441	0.149
Wang WL et al, 2014	1.190	0.934	1.517	1.405	0.160
Yildiz Y et al, 2013	1.229	0.969	1.559	1.697	0.090
Combined	1.217	0.970	1.528	1.696	0.090

AA vs GG+GA

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
Chen K et al, 2007	1.724	1.249	2.380	3.312	0.001
Cingeetham A et al , 2015	1.778	1.319	2.397	3.779	0.000
Dholariya et al 2016	1.657	1.219	2.252	3.226	0.001
Edathara PM et al, 2016	1.834	1.356	2.482	3.935	0.000
Javid J et al, 2015	1.422	1.008	2.007	2.006	0.045
Mirmajidi H et al , 2015	1.761	1.307	2.372	3.717	0.000
Mozhagan Moazami, 2016	1.826	1.329	2.508	3.719	0.000
Nuckel H et al, 2006	1.712	1.268	2.310	3.515	0.000
Oliveira C et al, 2014	1.817	1.344	2.458	3.878	0.000
Present study, 2017	1.725	1.280	2.325	3.585	0.000
Skogsberg A et al, 2006	1.831	1.349	2.485	3.884	0.000
Starczynski J et al, 2005	1.741	1.291	2.348	3.631	0.000
Wang WL et al, 2014	1.670	1.192	2.340	2.978	0.003
Combined	1.734	1.288	2.333	3.632	0.000

Supplementary Figure S3: Sensitivity analysis of BCL2 (-938) C>A polymorphism with overall cancer. The odds ratios (OR) are represented by the square, the 95% CIs are denoted by horizontal lines and the diamond signifies the pooled OR for each allelic and genetic combination



A vs C

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
Bachmann HS et al, 2007	0.988	0.816	1.196	-0.125	0.901
Christian DF et al, 2010	0.995	0.826	1.198	-0.055	0.956
Cingeetham A et al, 2015	0.958	0.795	1.154	-0.453	0.651
Hirata H et al, 2008	0.969	0.801	1.171	-0.331	0.741
Javid J et al, 2014	1.025	0.855	1.228	0.263	0.793
Lehnerdt GF et al, 2009	0.997	0.825	1.205	-0.027	0.979
Li W et al, 2014	0.957	0.795	1.152	-0.464	0.642
Meka PB et al, 2015	0.958	0.796	1.154	-0.449	0.654
Moghaddam E et al, 2017	1.010	0.838	1.217	0.102	0.919
Mou X et al, 2015	1.006	0.833	1.214	0.058	0.954
Pan W et al, 2015	1.002	0.817	1.229	0.023	0.982
Present study, 2017	0.935	0.784	1.116	-0.743	0.457
Wang WL et al, 2014	0.945	0.793	1.126	-0.628	0.530
Xu P et al, 2013	0.977	0.797	1.197	-0.224	0.823
Yang X et al, 2016	1.016	0.846	1.220	0.170	0.865
Zhang N et al, 2011	0.960	0.797	1.156	-0.433	0.665
Combined	0.981	0.818	1.175	-0.212	0.832

AA vs CC

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
Bachmann HS et al, 2007	0.953	0.637	1.426	-0.233	0.815
Christian DF et al, 2010	0.970	0.657	1.434	-0.150	0.880
Cingeetham A et al, 2015	0.922	0.615	1.380	-0.396	0.692
Hirata H et al, 2008	0.920	0.615	1.377	-0.404	0.686
Javid J et al, 2014	1.020	0.694	1.499	0.102	0.919
Lehnerdt GF et al, 2009	0.973	0.652	1.451	-0.134	0.893
Li W et al, 2014	0.883	0.599	1.301	-0.631	0.528
Meka PB et al, 2015	0.866	0.592	1.266	-0.744	0.457
Moghaddam E et al, 2017	1.009	0.684	1.488	0.046	0.963
Mou X et al, 2015	1.007	0.681	1.487	0.033	0.973
Pan W et al, 2015	0.975	0.629	1.513	-0.111	0.911
Present study, 2017	0.877	0.599	1.286	-0.671	0.503
Wang WL et al, 2014	0.847	0.594	1.208	-0.916	0.360
Xu P et al, 2013	0.930	0.605	1.429	-0.332	0.740
Yang X et al, 2016	1.008	0.684	1.486	0.040	0.968
Zhang N et al, 2011	0.885	0.601	1.305	-0.615	0.538
Combined	0.939	0.641	1.373	-0.326	0.744

CA vs CC

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
Bachmann HS et al, 2007	0.980	0.800	1.200	-0.200	0.842
Christian DF et al, 2010	0.968	0.794	1.181	-0.318	0.750
Cingeetham A et al, 2015	0.919	0.764	1.106	-0.894	0.371
Hirata H et al, 2008	0.950	0.777	1.162	-0.497	0.619
Javid J et al, 2014	0.998	0.817	1.220	-0.017	0.987
Lehnerdt GF et al, 2009	1.002	0.822	1.222	0.023	0.981
Li W et al, 2014	0.956	0.780	1.173	-0.429	0.668
Meka PB et al, 2015	0.972	0.792	1.192	-0.276	0.782
Moghaddam E et al, 2017	0.969	0.792	1.187	-0.302	0.763
Mou X et al, 2015	0.961	0.785	1.178	-0.379	0.705
Pan W et al, 2015	1.005	0.821	1.231	0.052	0.959
Present study, 2017	0.930	0.771	1.123	-0.754	0.451
Wang WL et al, 2014	0.955	0.777	1.172	-0.443	0.658
Xu P et al, 2013	0.964	0.778	1.195	-0.332	0.740
Yang X et al, 2016	1.015	0.834	1.234	0.144	0.885
Zhang N et al, 2011	0.963	0.786	1.178	-0.371	0.711
Combined	0.969	0.798	1.176	-0.322	0.747

AA+CA vs CC

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
Bachmann HS et al, 2007	0.970	0.770	1.221	-0.261	0.794
Christian DF et al, 2010	0.965	0.769	1.210	-0.308	0.758
Cingeetham A et al, 2015	0.923	0.739	1.152	-0.710	0.478
Hirata H et al, 2008	0.940	0.747	1.183	-0.527	0.598
Javid J et al, 2014	1.005	0.804	1.257	0.044	0.965
Lehnerdt GF et al, 2009	0.992	0.791	1.245	-0.065	0.948
Li W et al, 2014	0.936	0.744	1.178	-0.564	0.573
Meka PB et al, 2015	0.946	0.751	1.191	-0.475	0.635
Moghaddam E et al, 2017	0.974	0.774	1.226	-0.223	0.823
Mou X et al, 2015	0.969	0.767	1.222	-0.269	0.788
Pan W et al, 2015	0.991	0.782	1.255	-0.076	0.939
Present study, 2017	0.908	0.733	1.125	-0.880	0.379
Wang WL et al, 2014	0.928	0.742	1.162	-0.648	0.517
Xu P et al, 2013	0.951	0.744	1.217	-0.398	0.691
Yang X et al, 2016	1.007	0.809	1.254	0.067	0.947
Zhang N et al, 2011	0.942	0.749	1.183	-0.515	0.607
Combined	0.959	0.769	1.195	-0.375	0.707

AA vs CC+CA

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
Bachmann HS et al, 2007	0.986	0.705	1.379	-0.083	0.934
Christian DF et al, 2010	1.010	0.733	1.392	0.062	0.950
Cingeetham A et al, 2015	0.973	0.697	1.357	-0.163	0.870
Hirata H et al, 2008	0.969	0.694	1.352	-0.185	0.853
Javid J et al, 2014	1.043	0.759	1.433	0.261	0.794
Lehnerdt GF et al, 2009	0.986	0.706	1.376	-0.086	0.932
Li W et al, 2014	0.927	0.674	1.276	-0.464	0.643
Meka PB et al, 2015	0.909	0.667	1.240	-0.600	0.548
Moghaddam E et al, 2017	1.051	0.768	1.438	0.312	0.755
Mou X et al, 2015	1.050	0.767	1.437	0.305	0.760
Pan W et al, 2015	1.003	0.694	1.450	0.016	0.987
Present study, 2017	0.934	0.681	1.280	-0.427	0.669
Wang WL et al, 2014	0.888	0.666	1.185	-0.806	0.420
Xu P et al, 2013	0.974	0.682	1.391	-0.145	0.885
Yang X et al, 2016	1.030	0.743	1.428	0.178	0.859
Zhang N et al, 2011	0.930	0.677	1.278	-0.446	0.655
Comnined	0.978	0.715	1.337	-0.142	0.887

Supplementary Figure S3



Eggr's Regression: Intercept= 1.20, 95%CI= -1.26 to 3.68, P= 0.31
Begg & Mazumder test: Tau= 0.22, Tau_z=1.18, p=0.23

Eggr's Regression: Intercept= 1.60, 95%CI= -1.69 to 4.90, P= 0.31
Begg & Mazumder test: Tau= 0.02, Tau_z=0.13, p=0.89

Supplementary Figure S4

Supplementary Figure S4: Funnel Plot analysis. Panel A. represents the funnel plot analysis of A vs G of BAX -248 G>A. panel B represents the funnel plot analysis of A vs C of BCL2 (-938) C>A. Y-axis represents the Standard error and the X-axis represents the Odds Ratio. Each dot indicates the individual study. Dotted lines signify the 95% Confidence Interval. A solid line at the middle indicates the overall effect from the meta-analysis.